Adjuvant treatment of advanced-stage endometrial cancer

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 256-265

  Lee, Nita Karnik ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

doxorubicin; Endometrial cancer; recurrent; recurrent disease; TAP

Indexed keywords

ANASTROZOLE; BETA CATENIN; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GESTAGEN; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; IXABEPILONE; K RAS PROTEIN; LAPATINIB; MEDROXYPROGESTERONE; MEGESTROL ACETATE; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARCINOSARCOMA; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED SURGERY; CYTOREDUCTIVE SURGERY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; HYSTERECTOMY; LAPAROTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MINIMALLY INVASIVE SURGERY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RECEPTOR DOWN REGULATION; ROBOTICS; SALPINGOOOPHORECTOMY; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT;

EID: 79955550885     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318218c659     Document Type: Article

References (23)

1. NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. Version 1.2011. www.nccn.org.
2. Smith RS, Kapp DS, Chen Q, et al. Treatment of high-risk uterine cancer with whole abdominopelvic RT. Int J Radiat Oncol Biol Phys. 2000;48:767-778.
3. Sutton G, Axelrod JH, Bundy BT, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with Stage III and IV endometrial cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;97:755-763. (Pubitemid 40824643)
4. Randall ME, Filiaci VL, Muss H, et al. Randomized PHASE III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36-44. (Pubitemid 46630491)
5. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543-552.
6. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22: 3902-3908. (Pubitemid 41079871)
7. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin+ cisplatin versus doxorubicin+ 24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15:1173-1178. (Pubitemid 39199303)
8. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:277-281. (Pubitemid 36335809)
9. Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;103: 523-526. (Pubitemid 44740100)
10. Garcia A, Blessing J, Nolte S, et al.Aphase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;111:22-26.
11. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:2360-2364. (Pubitemid 34441664)
12. Dizon DS, Blessing JA, McMeekin S, et al. GOG-129P Phase II trial of Ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129P. J Clin Oncol. 2009;27:3104-3108.
13. Martin-Hirsch PPL, Jarvis GG, Kitchener HC, et al. Progestagens for endometrial cancer. Cochrane Database Syst Rev. 1999;3:CD001040. DOI: 10.1002/14651858. CD001040.
14. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response Study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744. (Pubitemid 29269242)
15. Fiorica M, Brunetto VL, Hanjani P, et al. Phase II trial of alternating course of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2004;91:10-14. (Pubitemid 38147365)
16. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2001;19:364-367. (Pubitemid 32112847)
17. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (Temsirolimus) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. Proc Am Soc Clin Oncol. 2006;24:121s. (abstr #3003).
18. Slomovitz BM, Lu KH, Johnston T, et al. A Phase 2 Study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial cancer. Cancer. 2010;116:5415-5419.
19. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2006.
20. ASCO Annual Meeting. Proceedings Part I 2007;25:18S. Abstract # 5516.
21. Aghajanian C, SillMW, Darcy K, et al.A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2009;27:284s. (ASCO#5531).
22. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase IIConsortia. Gynecol Oncol. 2010;117:37-40.
23. Correa R, Mackay H, Hirte HW, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California cancer phase II consortia. J Clin Oncol. 2010;28(15 suppl):ASCO#5038.